The cancer-vaccine option: finance the evidence before counting the payment
This research white paper examines a licensing option as a timed evidence-and-capital decision rather than guaranteed financing. Using the Merck–Moderna personalized cancer-vaccine collaboration as a historical reference, it distinguishes research funding, equity investment, and option exercise from later clinical milestones. A separate hypothetical cash model explores what an emerging biotechnology company must fund while evidence is gathered, what happens if an election or payment is delayed, and how to prepare if an option is never exercised. The practical implication is an evidence-ready decision package that connects clinical interpretation, manufacturing responsibilities, governance, settlement timing, and cash reserves. A probability-weighted future payment cannot substitute for available liquidity. The objective is to make both the upside commitment and the downside contingency executable.